DBV Technologies S.A. (NASDAQ:DBVT) Stock Has Consensus Target Price of $48.50 According to Analysts

Key Points

• Analysts maintain a “Moderate Buy” consensus on DBV Technologies, with five buy ratings and one sell rating. The average 12-month price target is $48.50.
• DBVT shares opened at $8.87, near their 12-month low of $8.86 and well below the 12-month high of $26.18, while the company has a market capitalization of approximately $557.7 million.
• Institutional investors and hedge funds own 71.74% of the stock. DBV Technologies is developing needle-free treatments for food allergies, led by its investigational Viaskin Peanut wearable patch.

DBV Technologies S.A. (NASDAQ:DBVT - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the six analysts that are currently covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell recommendation and five have issued a buy recommendation on the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $48.50.

DBVT has been the subject of a number of analyst reports. Cantor Fitzgerald reiterated an "overweight" rating on shares of DBV Technologies in a research report on Thursday, September 10th. Weiss Ratings cut DBV Technologies from a "sell (d-)" rating to a "sell (e+)" rating in a report on Friday, July 17th. Citizens Jmp increased their price target on DBV Technologies from $47.00 to $55.00 and gave the stock a "market outperform" rating in a research report on Tuesday, June 30th. Citigroup reiterated a "market outperform" rating on shares of DBV Technologies in a research report on Wednesday, September 30th. Finally, Wall Street Zen lowered DBV Technologies from a "hold" rating to a "sell" rating in a report on Saturday, July 4th.

DBV Technologies Trading Down 1.8%

Shares of NASDAQ:DBVT opened at $8.87 on Thursday. DBV Technologies has a 12-month low of $8.86 and a 12-month high of $26.18. The business has a 50 day moving average of $12.59 and a two-hundred day moving average of $15.93. The company has a market capitalization of $557.73 million, a PE ratio of -2.53 and a beta of -1.04.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in DBVT. Perceptive Advisors LLC acquired a new position in DBV Technologies during the first quarter worth $20,146,000. Vivo Capital LLC lifted its holdings in DBV Technologies by 8.4% during the first quarter. Vivo Capital LLC now owns 2,667,569 shares of the company's stock valued at $55,726,000 after purchasing an additional 205,943 shares in the last quarter. ADAR1 Capital Management LLC purchased a new position in DBV Technologies during the first quarter valued at $21,159,000. Royal Bank of Canada lifted its holdings in DBV Technologies by 167.1% during the first quarter. Royal Bank of Canada now owns 4,680 shares of the company's stock valued at $98,000 after purchasing an additional 2,928 shares in the last quarter. Finally, Elmind Capital LP acquired a new stake in shares of DBV Technologies in the first quarter valued at about $5,536,000. 71.74% of the stock is owned by institutional investors and hedge funds.

About DBV Technologies

DBV Technologies is a clinical-stage biopharmaceutical company focused on developing treatments for food allergies and other immune-mediated conditions. The company's technology is designed to deliver therapeutic proteins through the skin without needles, with the goal of gradually modifying the immune system's response to specific allergens.

DBV Technologies' principal product candidate is Viaskin Peanut, an investigational epicutaneous immunotherapy designed to expose patients to small amounts of peanut protein through a wearable patch.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.